Patents by Inventor Deborah L. Fuller

Deborah L. Fuller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200306367
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Application
    Filed: November 22, 2016
    Publication date: October 1, 2020
    Inventors: Edward CLARK, Deborah L. FULLER, Che-Leung LAW, Amanda MAK
  • Patent number: 10766929
    Abstract: Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 8, 2020
    Assignee: University of Washington
    Inventors: David Baker, Aaron Arthur Chevalier, Gabriel Jacob Rocklin, Christopher David Bahl, Lance Joseph Stewart, Daniel Adriano Silva Manzano, Deborah L. Fuller, Merika Treants Koday, Jason Gilmore
  • Publication number: 20200017552
    Abstract: Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 16, 2020
    Inventors: David BAKER, Aaron Arthur CHEVALIER, Gabriel Jacob ROCKLIN, Christopher David BAHL, Lance Joseph STEWART, Daniel Adriano SILVA MANZANO, Deborah L. FULLER, Merika TREANTS KODAY, Jason GILMORE
  • Patent number: 9771395
    Abstract: Designed polypeptides having the amino acid sequence of SEQ ID NQ: 1 are described that bind with high affinity and selectivity to the influenza hemagglutinin protein, and which can be used for treating and/or limiting an influenza infection, as well as diagnosing an influenza infection and identifying candidate compounds for treating an influenza infection.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: September 26, 2017
    Assignee: University of Washington
    Inventors: Merika Treants Koday, Deborah L. Fuller, Aaron Chevalier, Jorgen Nelson, David Baker
  • Publication number: 20170073375
    Abstract: Designed polypeptides having the amino acid sequence of SEQ ID NQ: 1 are described that bind with high affinity and selectivity to the influenza hemagglutinin protein, and which can be used for treating and/or limiting an influenza infection, as well as diagnosing an influenza infection and identifying candidate compounds for treating an influenza infection.
    Type: Application
    Filed: March 20, 2015
    Publication date: March 16, 2017
    Inventors: Merika Treants KODAY, Deborah L. FULLER, Aaron CHEVALIER, Jorgen NELSON, David BAKER
  • Patent number: 7022320
    Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two M. tuberculosis antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules having a sequence or sequences encoding one or more M. tuberculosis antigens are described. Methods of eliciting an immune response using these molecules and compositions are also described.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: April 4, 2006
    Assignee: PowderJect Vaccines, Inc.
    Inventors: Michael D. Macklin, Deborah L. Fuller
  • Patent number: 6881723
    Abstract: Recombinant nucleic acid molecules are described. The molecules have a first sequence encoding a Hepatitis B virus core antigen and a second sequence encoding at least one T cell epitope inserted within the first sequence. Vectors and compositions containing these molecules are also described. Methods of eliciting an immune response using these molecules are also described.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: April 19, 2005
    Assignee: Powderject Vaccines, Inc.
    Inventors: Deborah L. Fuller, James T. Fuller
  • Patent number: 6558961
    Abstract: Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the individual are provided.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: May 6, 2003
    Assignee: PowderJect Research Limited
    Inventors: David F. Sarphie, Lee K. Roberts, Deborah L. Fuller
  • Patent number: 6200959
    Abstract: An approach to genetic vaccine methodology is described. A genetic construction encoding antigenic determinants of a filovirus is transfected into cells of the vaccinated individuals using a particle acceleration protocol so as to express the viral antigens in healthy cells to produce an immune response to those antigens.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: March 13, 2001
    Assignee: PowerJect Vaccines Inc.
    Inventors: Joel R. Haynes, Connie S. Schmaljohn, Deborah L. Fuller, Alan Schmaljohn, Peter B. Jahrling
  • Patent number: 5470708
    Abstract: A method of genetically transforming mammalian unattached cells is disclosed. The method begins by preparing copies of a nucleic acid construct and coating these copies onto biologically inert carrier particles. Mammalian unattached cells are isolated in a liquid suspension. The cell suspension is placed on a target surface, wherein the liquid is spread to a thin film on the target surface. In an alternative embodiment of the present invention, the liquid is spread onto a porous surface. The cells are bombarded with the construct-coated particles in such a fashion that some particles lodge in the interior of at least some of the cells. The existence and expression of the construct within the cell is verified.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: November 28, 1995
    Inventors: Ning-Sun Yang, William F. Swain, Joseph K. Burkholder, Deborah L. Fuller